Valuation : Valneva SE

Market Cap 548M 636M 519M 470M 882M 60.73B 886M 6.16B 2.37B 30.9B 2.39B 2.33B 97.63B P/E 2026 *
-6.63x
P/E 2027 * 10.5x
Enterprise Value 681M 791M 645M 585M 1.1B 75.56B 1.1B 7.66B 2.95B 38.44B 2.97B 2.91B 121B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 2.15x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-2.27%
Current month+6.65%
1 month+16.45%
3 months+30.44%
6 months-39.63%
Current year-22.32%
1 week 2.83
Extreme 2.826
2.98
1 month 2.29
Extreme 2.292
3.24
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.34
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%-2.27%-25.72%-54.68% 636M
-0.71%-6.35%-4.87%+9.03% 45.48B
+0.21%-2.98%+340.68%+519.93% 43.69B
+1.74%-2.24%+37.28%+21.57% 43.09B
+1.38%-3.28%+3.23%+65.60% 39.4B
-1.44%-5.26%+8.78%+36.85% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+18.07%+110.32% 16.4B
-0.31%-2.78%+10.47%+30.49% 14.24B
+1.93%-3.55%+74.20%+39.37% 13.28B
Average +0.41%-3.44%+51.35%+86.50% 26.54B
Weighted average by Cap. +0.41%-3.66%+72.91%+123.11%

Financials

2026 *2027 *
Net sales 151M 175M 143M 130M 243M 16.74B 244M 1.7B 653M 8.52B 658M 644M 26.92B 283M 329M 268M 243M 456M 31.42B 459M 3.19B 1.23B 15.99B 1.24B 1.21B 50.51B
Net income -81.11M -94.14M -76.8M -69.62M -131M -8.99B -131M -912M -351M -4.58B -354M -346M -14.46B 53.07M 61.6M 50.25M 45.55M 85.45M 5.88B 85.89M 597M 230M 2.99B 231M 226M 9.46B
Net Debt 134M 155M 127M 115M 215M 14.83B 216M 1.5B 578M 7.54B 583M 570M 23.84B 62.48M 72.51M 59.16M 53.62M 101M 6.93B 101M 703M 270M 3.52B 272M 266M 11.14B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
11/09/26 €2.888 -0.31% 342,746
10/09/26 €2.897 -0.03% 487,692
09/09/26 €2.898 -2.52% 359,270
08/09/26 €2.973 +2.87% 424,243
07/09/26 €2.890 -2.20% 346,523
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.888EUR
Average target price
6.193EUR
Spread / Average Target
+114.43%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!